Shedrx GLP-1 Review: Program Structure & Clinical Considerations

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Shedrx GLP-1 is a telehealth program offering compounded semaglutide and tirzepatide to eligible patients seeking weight management support. The platform uses physician-guided protocols and monthly consultations, though individual response and tolerability vary significantly based on metabolic and genetic factors.

Choosing a GLP-1 program requires understanding not just medication availability and cost, but also how your underlying biology may influence treatment response. Precision-wellness approaches that incorporate genetic context alongside clinical evaluation can help patients and providers align on realistic expectations and optimal dosing strategies.

How Shedrx Structures Its GLP-1 Program Model

Shedrx operates as a telehealth-first platform connecting patients with licensed physicians for initial intake, medication prescription, and ongoing monitoring. The program sources compounded semaglutide and tirzepatide from licensed 503A pharmacies, ensuring regulatory compliance and product consistency throughout treatment.

Monthly consultations form the backbone of Shedrx's model, allowing dose adjustments based on patient response and side effect tolerance. This iterative approach acknowledges that GLP-1 dosing is not static—individual metabolic response, gastrointestinal tolerance, and weight loss trajectory inform provider recommendations over time.

Medication Options and Genetic Context in Treatment Selection

Shedrx offers compounded semaglutide and tirzepatide as primary treatment options. Semaglutide targets GLP-1 receptors alone, while tirzepatide activates both GLP-1 and GIP receptors, potentially offering broader metabolic engagement. Genetic variants in GLP1R, GIPR, and other peptide pathway genes may influence individual response patterns.

Medication Option	Key Mechanism	Genetic Predisposition Context	Clinical Consideration
Compounded Semaglutide	GLP-1 receptor agonist	GLP1R variants (rs6923761) may influence receptor sensitivity	Foundational GLP-1 therapy; established safety profile in weight management trials
Compounded Tirzepatide	GLP-1 + GIP receptor agonist	GIPR variants (rs1800437) may relate to dual-pathway response potential	Dual mechanism may offer additional glycemic and weight benefits; emerging clinical data supports broader efficacy
Dose Escalation Strategy	Gradual titration over weeks	Individual tolerance influenced by metabolic genetics and gut sensitivity	Weekly or biweekly increments allow provider adjustment based on patient response
Genetic Testing Relevance	Precision Peptide assessment	Predispositions in peptide pathways inform treatment context	May support more informed provider-patient conversations about expected response patterns

Eligibility Criteria and Clinical Evaluation Requirements

Shedrx typically requires patients to have a BMI of 25 or higher with weight-related health conditions, or BMI of 30 or higher regardless of comorbidities—similar to FDA guidance for GLP-1 medications. A physician consultation evaluates baseline metabolic health, medications, and contraindications before prescription.

Baseline bloodwork assessing kidney function, liver health, and metabolic markers informs whether GLP-1 therapy is appropriate and guides initial dosing. Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 are typically excluded from GLP-1 treatment.

Safety Considerations and Long-Term Provider Partnerships

Common GLP-1 side effects include nausea, vomiting, and gastrointestinal symptoms, typically mild and transient during dose escalation. Serious side effects are rare but include pancreatitis, gallbladder complications, and acute kidney injury—requiring immediate medical attention and close provider monitoring, especially during initial weeks.

Sustained GLP-1 therapy depends on regular provider communication, consistent follow-up appointments, and willingness to adjust doses or switch medications if tolerance or efficacy concerns emerge. Genetic predispositions in appetite regulation (FTO rs9939609) and insulin secretion (MC4R rs17782313) may contextually influence how quickly weight loss stabilizes and whether additional pharmacological support is needed.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes—regions that may provide context regarding individual peptide pathway activation and metabolic response patterns. These insights may help provide context for provider-patient conversations about expected treatment trajectory, though genetic predisposition does not determine exact medication response or guarantee outcomes.

The genetic test reveals predispositions in peptide pathways relevant to appetite signaling and weight regulation. For instance, specific GIPR variants may suggest whether dual GLP-1/GIP therapy (tirzepatide) aligns better with your biological profile than GLP-1-only approaches. This information should be interpreted with a qualified healthcare provider as part of a comprehensive clinical evaluation.

Understanding your genetic predispositions in appetite and metabolic pathways can support a more informed conversation with your provider about medication selection, expected dosing progression, and realistic timelines for weight loss. Combined with baseline metabolic biomarkers and clinical history, genetic context empowers shared decision-making rather than trial-and-error treatment approaches.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is Shedrx GLP-1 and how does it differ from in-office weight management programs?

Shedrx is a telehealth platform connecting patients with physicians for compounded GLP-1 prescriptions and monthly monitoring. Virtual-first delivery reduces appointment friction and overhead costs compared to traditional clinic visits, though clinical oversight and dose adjustments follow similar protocols.

Does Shedrx prescribe branded GLP-1 drugs like Ozempic or Wegovy?

No. Shedrx focuses on compounded semaglutide and tirzepatide from licensed 503A pharmacies. Compounded formulations are not FDA-approved medications but are regulated under pharmacy practice laws and may offer cost and access advantages for eligible patients.

How much does Shedrx GLP-1 treatment cost per month?

Shedrx pricing varies by medication and dose; typical costs range from $149/mo monthly for compounded semaglutide or tirzepatide. Consultation fees and pharmacy costs may apply separately. Insurance coverage for compounded medications is limited, so out-of-pocket expense should be confirmed upfront.

What genetic factors might influence how my body responds to GLP-1 medication?

Variants in GLP1R, GIPR, FTO, and MC4R genes relate to appetite signaling and metabolic regulation. The Precision Peptide Genetic Test may reveal predispositions in these pathways, providing context for provider discussions—though genetics alone does not predict exact medication response or weight loss magnitude.

Are GLP-1 medications safe long-term, and who should not use them?

GLP-1 therapy is generally safe for eligible candidates when prescribed and monitored by a qualified provider. Contraindications include personal/family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, and severe kidney or liver disease.

Shedrx GLP-1: Evaluating Program Design and Personalized Treatment Pathways